ストックスクリーナーアプリを入手
0.6799
0.00%
0.00
前日終値:
$0.6799
開ける：
$0.7
24時間の取引高:
549.23K
Relative Volume:
0.38
時価総額：
$2.53M
収益：
-
当期純損益:
$-9.64M
株価収益率:
-0.0982
EPS:
-6.9236
ネットキャッシュフロー:
$-10.11M
1週間 パフォーマンス:
-3.72%
1か月 パフォーマンス:
-15.54%
6か月 パフォーマンス:
-69.51%
1年 パフォーマンス:
-66.83%
1日の値動き範囲:
$0.68
$0.7299
1週間の範囲:
$0.6443
$1.37
52週間の値動き範囲:
$0.55
$4.10
Gt Biopharma Inc Stock (GTBP) Company Profile
名前
Gt Biopharma Inc
セクター
電話
(800) 304-9888
住所
505 MONTGOMERY STREET, SAN FRANCISCO
GTBP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
4.642 | 5.31B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.88 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.445 | 113.25M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2008 | 445.05M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.00 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-02 | 開始されました | ROTH MKM | Buy |
| 2021-05-24 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-13 | 開始されました | B. Riley Securities | Buy |
| 2021-03-17 | 開始されました | ROTH Capital | Buy |
Gt Biopharma Inc (GTBP) 最新ニュース
Will GT Biopharma Inc. stock benefit from automationM&A Rumor & Long-Term Safe Investment Ideas - newser.com
Tools to assess GT Biopharma Inc.’s risk profile2025 Market Outlook & Momentum Based Trading Ideas - newser.com
Visual trend scoring systems applied to GT Biopharma Inc.Earnings Overview Summary & Low Drawdown Momentum Trade Ideas - newser.com
Strategies to average down on GT Biopharma Inc.Fed Meeting & Safe Entry Zone Tips - newser.com
Will GT Biopharma Inc. continue its uptrendQuarterly Market Summary & Advanced Swing Trade Entry Alerts - newser.com
GT Biopharma Inc OXIA Stock Analysis and ForecastEconomic Data Impact & Investment Recommendations You Can Trust - earlytimes.in
Chart based analysis of GT Biopharma Inc. trendsStop Loss & Weekly High Potential Stock Alerts - newser.com
Using economic indicators to assess GT Biopharma Inc. potentialMarket Growth Summary & Breakout Confirmation Alerts - newser.com
GT Biopharma Inc. stock volume spike explainedPortfolio Growth Summary & AI Driven Stock Reports - newser.com
Will GT Biopharma Inc. (OXIA) stock test record highs in 2025Quarterly Trade Report & Trade Opportunity Analysis Reports - newser.com
GT Biopharma Inc. stock trend forecastWeekly Profit Report & Fast Moving Market Watchlists - newser.com
Why GT Biopharma Inc. stock is seen as undervaluedPortfolio Performance Report & Long-Term Growth Portfolio Plans - newser.com
GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally - Stocktwits
Using data filters to optimize entry into GT Biopharma Inc.Insider Selling & Consistent Profit Alerts - newser.com
GT Biopharma advances Phase 1 trial of NK cell therapy with no safety issues - Investing.com Nigeria
Stocks In Play: GT Biopharma Inc - Barchart.com
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 - 富途牛牛
GT Biopharma provides enrollment update on GTB-3650 Phase 1 trial in patients with relapsed or refractory (R/R) CD33 expressing hematologic malignancies - MarketScreener
GT Biopharma Reports Successful Phase 1 Trial Progress for GTB-3650 in Hematologic Malignancies - Quiver Quantitative
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 - GlobeNewswire
GT Biopharma Initiates Cohort 3 Dosing; No DLTs, Cohort 4 Planned | GTBP Stock News - Stock Titan
EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers - Yahoo Finance
GT Biopharma Inc - Menafn.com
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion - MarketScreener
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms - Eastern Progress
Precision Oncology Pipeline Advances from Detection Through Targeted Destruction - The Globe and Mail
GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit - GlobeNewswire
Oct 28–29: GT Biopharma CEO Michael Breen to Attend Bahamas Summit; One-on-one Meetings Available - Stock Titan
Key metrics from GT Biopharma Inc.’s quarterly dataBond Market & Weekly Momentum Stock Picks - newser.com
How GT Biopharma Inc. (OXIA) stock reacts to new regulationsJuly 2025 Short Interest & Technical Entry and Exit Tips - newser.com
What’s the recovery path for long term holders of GT Biopharma Inc.Market Volume Summary & Expert Curated Trade Setups - newser.com
What drives GT Biopharma Inc stock priceChart Pattern Recognition & Small Capital Trading Growth - earlytimes.in
Will GT Biopharma Inc. (OXIA) stock profit from automation wave2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com
GT Biopharma Inc Stock Analysis and ForecastHead and Shoulders Patterns & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in
Can swing trading help recover from GT Biopharma Inc. lossesTrade Analysis Summary & AI Enhanced Market Trend Forecasts - newser.com
Gt Biopharma Inc (GTBP) 財務データ
収益
当期純利益
現金流量
EPS
1.09%
大文字化:
|
ボリューム (24 時間):